ALK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy

BACKGROUND. Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well‐established therapy target in non‐small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non‐NSCLC tumors and report their responsiveness...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Ross, Jeffrey S., Ali, Siraj M., Fasan, Omotayo, Block, Jared, Pal, Sumanta, Elvin, Julia A., Schrock, Alexa B., Suh, James, Nozad, Sahar, Kim, Sungeun, Jeong Lee, Hwa, Sheehan, Christine E., Jones, David M., Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Miller, Vince A., Stephens, Philip J., Gay, Laurie M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Cancer Diagnostics and Molecular Pathology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728036/
https://ncbi.nlm.nih.gov/pubmed/29079636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0488
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi